1-Boc-3-碘-1H-吲唑 | 290368-00-2

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 1-Boc-3-碘-1H-吲唑
• 中文别名: N-(叔丁氧羰基)-3-碘吲唑
• 英文名称: tert-butyl 3-iodo-1H-indazole-1-carboxylate
• 英文别名: tert-butyl 3-iodoindazole-1-carboxylate
• CAS: 290368-00-2
• 化学式: C₁₂H₁₃IN₂O₂
• mdl: MFCD09835520
• 分子量: 344.152
• InChiKey: DHNSGIOEVGLLOI-UHFFFAOYSA-N

物化性质

• 熔点：
  117℃
• 密度：
  1.65

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Boc-3-iodo-1h-indazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Boc-3-iodo-1h-indazole
CAS number: 290368-00-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H13IN2O2
Molecular weight: 344.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen Iodide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-Boc-3-碘-1H-吲唑 在 palladium 10% on activated carbon 、 水 、 氢气 、 palladium diacetate 、 三对苯甲基膦 、 lithium hydroxide 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 20.0 ℃ 、344.75 kPa 条件下， 反应 37.0h， 生成 3-(1H-indazol-3-yl) propanoic acid
  参考文献：
  名称：

  [EN] CYCLIC AMIDE DERIVATIVES AS INHIBITORS OF 11 - BETA - HYDROXYSTEROID DEHYDROGENASE AND USES THEREOF
  [FR] DÉRIVÉS D'AMIDE CYCLIQUES À UTILISER EN TANT QU'INHIBITEURS DE 11-BÊTA-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE ET UTILISATIONS DE CEUX-CI

  摘要：

  本发明涉及某些酰胺衍生物，这些衍生物具有抑制11-β-羟基类固醇脱氢酶1型（11β-HSD-1）的能力，因此在预防或治疗可通过抑制该酶来预防或治疗的某些疾病中是有用的。此外，本发明还涉及这些化合物的制备方法、含有这些化合物的药物组合物以及这些化合物在治疗某些疾病中的用途。预计本发明的化合物将用于治疗非胰岛素依赖型2型糖尿病（NIDDM）、胰岛素抵抗、肥胖、空腹血糖受损、葡萄糖耐量受损、脂质紊乱（如血脂异常）、高血压以及其它疾病和状况。

  公开号：

  WO2013128465A1
• 作为产物：
  描述：

  吲唑 在 4-二甲氨基吡啶 、 碘 、 三乙胺 、 potassium hydroxide 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 11.0h， 生成 1-Boc-3-碘-1H-吲唑
  参考文献：
  名称：

  机械化学合成固定在硅胶上的 PdO2 纳米颗粒，用于催化 Suzuki-Miyaura 交叉偶联反应，导致 1H-吲唑与苯基硼酸的 C-3 修饰

  摘要：

  1H-吲唑的 C-3 修饰已生产出用于治疗癌症和 HIV 的活性药物。但到目前为止，由于反应性较低的 C-3 位点缺乏有效的 CC 键形成，这种转化似乎不太可行。在这项工作中，通过球磨硅胶与二价钯前体制备了一系列尺寸为 25-66 nm 的硅胶负载的 PdO2 纳米粒子，然后用作 1H-吲唑衍生物与苯硼酸。所有合成的催化剂均表现出比其钯前体更高的交叉偶联产率，并且还可以在甲苯/水/乙醇混合溶剂中重复使用3次而不会失去高活性和选择性。尽管钯前驱体的活性顺序为 PdCl2(dppf, 1,1'-双(二苯基膦)二茂铁) > PdCl2(dtbpf, 1,1'-双(二叔丁基膦)二茂铁) > Pd(OAc,醋酸盐）2，合成的催化剂表现出C1（来自Pd（OAc）2）> C3（来自PdCl2（dtbpf））> C2（来自PdCl2（dppf））的顺序，这符合BET（Brunauer-Emmett）的顺序

  DOI：

  10.3390/molecules28207190

文献信息

• CYCLIC AMIDE DERIVATIVES AS INHIBITORS OF 11 - BETA - HYDROXYSTEROID DEHYDROGENASE AND USES THEREOF
  申请人：CONNEXIOS LIFE SCIENCES PVT. LTD.

  公开号：US20150158860A1

  公开（公告）日：2015-06-11

  The present invention relates to certain amide derivatives that have the ability to inhibit 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) and which are therefore useful in the treatment of certain disorders that can be prevented or treated by inhibition of this enzyme. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders. It is expected that the compounds of the invention will find application in the treatment of conditions such as non-insulin dependent type 2 diabetes mellitus (NIDDM), insulin resistance, obesity, impaired fasting glucose, impaired glucose tolerance, lipid disorders such as dyslipidemia, hypertension and as well as other diseases and conditions.

  本发明涉及某些酰胺衍生物，这些衍生物具有抑制11-β-羟基类固醇脱氢酶1型（11β-HSD-1）的能力，因此在预防和治疗可以通过抑制该酶来预防或治疗的某些疾病中是有用的。此外，发明还涉及这些化合物的制备方法、含有这些化合物的药物组合物以及这些化合物在治疗某些疾病中的用途。预计本发明的化合物将在治疗非胰岛素依赖型2型糖尿病（NIDDM）、胰岛素抵抗、肥胖、空腹血糖受损、葡萄糖耐量受损、脂质紊乱（如血脂异常）、高血压以及其他疾病和状况中找到应用。
• Tryptophan-derived butyrylcholinesterase inhibitors as promising leads against Alzheimer's disease
  作者：Anže Meden、Damijan Knez、Marko Jukič、Xavier Brazzolotto、Marija Gršič、Anja Pišlar、Abida Zahirović、Janko Kos、Florian Nachon、Jurij Svete、Stanislav Gobec、Uroš Grošelj

  DOI：10.1039/c9cc01330j

  日期：——

  Tryptophan-derived selective nanomolar butyrylcholinesterase inhibitors with great potential for symptomatic therapy against Alzheimer's disease are disclosed.

  色氮氨酸衍生的选择性纳摩尔丁酰胆碱酯酶抑制剂揭示了对抗阿尔茨海默病症状治疗具有巨大潜力。
• [EN] SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE<br/>[FR] INHIBITEURS SÉLECTIFS DE MUTANTS CLINIQUEMENT IMPORTANTS DE LA TYROSINE KINASE DE L'EGFR
  申请人：CS PHARMASCIENCES INC

  公开号：WO2017120429A1

  公开（公告）日：2017-07-13

  The present invention provides compounds of Formula (I) or a subgeneric structure or species thereof, or a pharmaceutically acceptable salt, ester, solvate, and/or prodrug thereof, and methods and compositions for treating or ameliorating abnormal cell proliferative disorders, such as cancer, wherein A, R2, R3, R10, E1, E2, E3, Y, and Z are as defined herein.

  本发明提供了式（I）的化合物或其亚类结构或种属，或其药学上可接受的盐、酯、溶剂化合物和/或前药，以及用于治疗或改善异常细胞增殖性疾病，如癌症的方法和组合物，其中A、R2、R3、R10、E1、E2、E3、Y和Z如本文所定义。
• ML212: A small-molecule probe for investigating fluconazole resistance mechanisms in <i>Candida albicans</i>
  作者：Willmen Youngsaye、Cathy L Hartland、Barbara J Morgan、Amal Ting、Partha P Nag、Benjamin Vincent、Carrie A Mosher、Joshua A Bittker、Sivaraman Dandapani、Michelle Palmer、Luke Whitesell、Susan Lindquist、Stuart L Schreiber、Benito Munoz

  DOI：10.3762/bjoc.9.171

  日期：——

  The National Institutes of Health Molecular Libraries and Probe Production Centers Network (NIH-MLPCN) screened >300,000 compounds to evaluate their ability to restore fluconazole susceptibility in resistant Candida albicans isolates. Additional counter screens were incorporated to remove substances inherently toxic to either mammalian or fungal cells. A substituted indazole possessing the desired bioactivity profile was selected for further development, and initial investigation of structure–activity relationships led to the discovery of ML212.

  国家卫生研究院分子图书馆和探针生产中心网络（NIH-MLPCN）筛选了超过300,000种化合物，以评估它们恢复对耐药念珠菌的氟康唑敏感性的能力。还加入了额外的对照筛选，以去除对哺乳动物或真菌细胞有毒的物质。选择了具有所需生物活性特征的取代吲唑化合物进行进一步开发，并初步研究结构-活性关系导致了ML212的发现。
• BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS
  申请人：Atobe Masakazu

  公开号：US20100029733A1

  公开（公告）日：2010-02-04

  A nitrogen-containing bicyclic heterocyclic compound represented by the following formula (1) is provided. When the compound or a salt thereof is administered to a human being or an animal, the compound has a strong antagonistic action against EP1 receptors, and is useful, for example, as an active ingredient of a medicine for the prevention and/or treatment of overactive bladder. The compound is also useful as an active ingredient of a medicine for the prevention and/or treatment of symptoms such as frequency urinary, urinary urgency, or urinary incontinence.

  提供一种由以下式（1）表示的含氮双环杂环化合物。当该化合物或其盐被用于人类或动物时，该化合物对EP1受体具有强烈的拮抗作用，并且可用作预防和/或治疗膀胱过度活跃的药物的活性成分。该化合物还可用作预防和/或治疗频繁排尿、尿急或尿失禁等症状的药物的活性成分。